NewLimit Secures $130M to Advance Age-Reversing Cell Therapies

NewLimit, founded by Coinbase’s Brian Armstrong, raises $130M to develop AI-powered age-reversing treatments. See what’s next for longevity science.
Matilda
NewLimit Secures $130M to Advance Age-Reversing Cell Therapies
NewLimit Secures $130 Million to Develop Breakthrough Age-Reversing Treatments Curious about NewLimit’s mission to reverse aging and extend healthy lifespans? Founded by Coinbase CEO Brian Armstrong, NewLimit has raised $130 million in Series B funding to accelerate its development of age-reversing treatments using advanced AI and genetic programming. This milestone highlights a growing wave of biotech innovation focused on epigenetic reprogramming, longevity medicine, and regenerative therapies — critical areas gaining massive investor interest in 2025.                   Image Credits:Steve Jennings / Getty Images The Series B round was led by venture powerhouse Kleiner Perkins, with participation from notable names like Nat Friedman, Daniel Gross, and Khosla Ventures. Returning investors such as Founders Fund, Dimension Capital, Elad Gil, Garry Tan, and Patrick Collison also doubled down on NewLimit’s potential, signaling strong confidence in the company's vision to reshape the fut…